Biological evaluation of 7-O-amide hesperetin derivatives as multitarget-directed ligands for the treatment of Alzheimer's disease

Mingfei Wu,Xingxing Zhu,Yilong Zhang,Min Wang,Tongtong Liu,Jianfei Han,Jun Li,Zeng Li
DOI: https://doi.org/10.1016/j.cbi.2020.109350
2021-01-01
Abstract:<p>A series of 7-O-amide hesperetin derivatives were subjected to multi-target biological evaluation of anti-Alzheimer's disease. Most of the compounds showed good in vitro inhibitory activity against cholinesterase, of which compound <strong>7c</strong> (7-O-(4-(morpholinoethyl)-acetamide) hesperetin) was the most effective anti-eqBuChE derivative (IC<sub>50</sub> = 0.28 ± 0.05 μM) and exerted neuroprotective effects. Further biological evaluation found that compounds <strong>4d</strong>, <strong>4e</strong> and <strong>7c</strong> showed strong antioxidant, anti-Aβ self-aggregation and anti-neuroinflammatory activities. Compound <strong>7c</strong> could inhibit the expression of iNOS and COX-2 proteins and prevent LPS-induced inflammatory response in BV2 cells. In addition, compound <strong>7c</strong> could chelate biometal ions such as Cu<sup>2+</sup> and Zn<sup>2+</sup>. In the vivo study, the MWM test confirmed that compound <strong>7c</strong> could improve the cognitive impairment caused by scopolamine. In summary, the above studies have shown that the optimized compound <strong>7c</strong> has great development potential as MTDL for the treatment of AD.</p>
pharmacology & pharmacy,biochemistry & molecular biology,toxicology
What problem does this paper attempt to address?